AR085502A1 - Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen - Google Patents

Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen

Info

Publication number
AR085502A1
AR085502A1 ARP120100641A ARP120100641A AR085502A1 AR 085502 A1 AR085502 A1 AR 085502A1 AR P120100641 A ARP120100641 A AR P120100641A AR P120100641 A ARP120100641 A AR P120100641A AR 085502 A1 AR085502 A1 AR 085502A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
heteroaryl
heterocycloalkyl
aryl
Prior art date
Application number
ARP120100641A
Other languages
English (en)
Spanish (es)
Inventor
Alan P Florjancic
Thomas D Penning
Yunsong Tong
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR085502A1 publication Critical patent/AR085502A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ARP120100641A 2011-02-28 2012-02-28 Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen AR085502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161447405P 2011-02-28 2011-02-28

Publications (1)

Publication Number Publication Date
AR085502A1 true AR085502A1 (es) 2013-10-09

Family

ID=46000328

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100641A AR085502A1 (es) 2011-02-28 2012-02-28 Inhibidores triciclicos de quinasas utiles como agentes anticancerigenos y composiciones farmaceuticas que los contienen

Country Status (11)

Country Link
US (1) US8710065B2 (enExample)
EP (1) EP2681221B1 (enExample)
JP (1) JP5886326B2 (enExample)
CN (1) CN103703005A (enExample)
AR (1) AR085502A1 (enExample)
CA (1) CA2827648A1 (enExample)
ES (1) ES2587514T3 (enExample)
MX (1) MX340402B (enExample)
TW (1) TWI532742B (enExample)
UY (1) UY33925A (enExample)
WO (1) WO2012161812A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015029447A1 (ja) * 2013-08-30 2015-03-05 興和株式会社 光学活性カルビノール化合物の製造方法
GB201322602D0 (en) * 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CA2945196C (en) * 2014-04-10 2020-02-18 Dalhousie University Treatment of parkinson's disease through arfgap1 inhibition
EP3185860A4 (en) 2014-08-29 2018-08-29 The Board of Regents of the University of Texas System Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA3043945A1 (en) 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones
JP6717457B2 (ja) * 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019011228A1 (zh) * 2017-07-10 2019-01-17 上海瑛派药业有限公司 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
EP3661917B1 (en) * 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
CN107821390A (zh) * 2017-10-13 2018-03-23 南京扬子鸿利源化学品有限责任公司 一种甲基磺草酮油悬浮剂及其制备方法
EP3712150B1 (en) 2017-11-01 2024-06-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
CN108727249A (zh) * 2018-07-07 2018-11-02 台州学院 3-二氟甲基哌啶盐酸盐及其衍生物的合成方法
WO2020063788A1 (zh) * 2018-09-27 2020-04-02 贝达药业股份有限公司 Fgfr4抑制剂及其应用
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
JP7481336B2 (ja) 2018-10-26 2024-05-10 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ｗｅｅ１阻害剤としてのピリミドピラゾロン類誘導体及びその使用
AU2020215088A1 (en) 2019-02-01 2021-07-22 Bayer Aktiengesellschaft 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
LT3964510T (lt) 2019-04-30 2024-08-12 Wuxi Biocity Biopharmaceutics Co., Ltd. Wee1 inhibitorinio junginio kristalinė forma ir jos panaudojimas
WO2020223558A1 (en) * 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021030537A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CR20220170A (es) 2019-10-11 2022-10-10 Incyte Corp Aminas bicíclicas como inhibidoras de la cdk2
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021073491A1 (zh) * 2019-10-16 2021-04-22 上海瑛派药业有限公司 二氢咪唑并嘧啶并嘧啶酮类化合物
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
TWI823255B (zh) * 2021-02-19 2023-11-21 大陸商微境生物醫藥科技(上海)有限公司 作為Wee-1抑制劑的稠環化合物
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4332104A4 (en) * 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
WO2025188106A1 (ko) * 2024-03-08 2025-09-12 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE412642T1 (de) 2003-07-25 2008-11-15 Novartis Ag Inhibitoren von p-38-kinase
US20050070554A1 (en) * 2003-08-27 2005-03-31 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20050250836A1 (en) * 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
AR058277A1 (es) 2005-12-09 2008-01-30 Solvay Pharm Gmbh N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion
WO2008072779A1 (ja) * 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
EP2213673B1 (en) * 2007-10-23 2013-06-05 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CA2745970A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative

Also Published As

Publication number Publication date
US20120220572A1 (en) 2012-08-30
JP5886326B2 (ja) 2016-03-16
CA2827648A1 (en) 2012-11-29
TW201247675A (en) 2012-12-01
TWI532742B (zh) 2016-05-11
EP2681221B1 (en) 2016-05-18
EP2681221A1 (en) 2014-01-08
US8710065B2 (en) 2014-04-29
UY33925A (es) 2012-09-28
JP2014506929A (ja) 2014-03-20
ES2587514T3 (es) 2016-10-25
CN103703005A (zh) 2014-04-02
MX2013009873A (es) 2014-03-12
MX340402B (es) 2016-07-07
WO2012161812A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
AR120339A2 (es) CRISTALES DE SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
ES2528451T3 (es) Inhibidores de esfingosina cinasa
AR107127A1 (es) Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
EA201390199A1 (ru) 2-замещенные-8-алкил-7-оксо-7,8-дигидропиридо[2,3-d]пиримидин-6-карбонитрилы и их применение
AR076794A1 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CL2016001537A1 (es) Inhibidores de syk
CL2014002220A1 (es) Compuesto 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)urea, inhibidor de la cinasa raf; forma cristalina del compuesto; composicion farmaceutica que lo comprende; y metodo para tratar el cancer.
SMT201500200B (it) Derivati di imidazo[1,2-a]piridina come inibitori delle chinasi fgfr per l'uso in terapia
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
MA32405B1 (fr) SELS DE 2-FLUORO-N-MÉTHYL-4-[7-(QUINOLÉIN-6-YL-MÉTHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE ET PROCÉDÉS ASSOCIÉS à LEUR PRÉPARATION
AR070535A1 (es) Compuestos inhibidores de raf y metodos para usarlos
CO6801740A2 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
JOP20190143B1 (ar) مثبطات جزيئات صغيرة من عائلة jak لإنزيمات الكيناز
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
CL2014000343A1 (es) Procedimientos de preparacion de compuesto polimorfico derivado de pirazolo[3,4-d]pirimidina; sal del compuesto; composicion farmaceutica que lo comprende y su uso en el tratamiento de un trastorno asociado a mtor.
IL230511B (en) (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridin-2- l) Benzamide as a btk inhibitor
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
MX381849B (es) Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y métodos para su uso.
IT1403661B1 (it) Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
EP3543242C0 (en) COMPOUND 8,9-DIHYDROIMIDAZOLE [1,2-A]PYRIMIDO [5,4-E]PYRIMIDINE -5 (6H)-KETONE
IL229606A0 (en) Pyrazolone [3, 4-d] pyrimidine compounds and their use as 2pde inhibitors and/or 4a3 cyp inhibitors
NI201400101A (es) Inhibidores de cinasa de fosfoinositida 3 cristalina
DK3597649T3 (da) Sammensætninger indeholdende substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer

Legal Events

Date Code Title Description
FB Suspension of granting procedure